Double Bond Pharmaceutical

Double Bond Pharmaceutical is a private, preclinical-stage biotech company leveraging its proprietary BeloGal® drug delivery platform to enhance the efficacy and safety of existing medicines. The company's strategy centers on reformulating proven drugs for targeted local or organ-specific delivery, with lead programs in oncology and infectious diseases. Based in Uppsala, Sweden, DBP aims to address significant unmet needs in glioblastoma, liver cancer, and pneumonia by improving therapeutic profiles and reducing systemic toxicity.

BeloGal®: A first-in-class, biomimetic drug delivery system using a polymer- and biology-free excipient to encapsulate APIs for targeted organ delivery or local sustained release, often combined with hydrogel technology for intracavitary administration.

DBP competes in the crowded field of drug delivery and reformulation, facing competition from other specialty pharma companies, academic spin-offs, and internal efforts by large pharmaceutical firms. Its success depends on demonstrating that BeloGal® offers a unique and clinically superior targeting profile compared to other technologies like liposomes, nanoparticles, or polymer-based depots.